Skip to main content

Site notifications

Gentamicin 40mg/mL (80mg in 2mL) Solution for Injection Ampoules (Amdipharm, UK)

Section 19A approved medicine
Gentamicin 40mg/mL (80mg in 2mL) Solution for Injection Ampoules (Amdipharm, UK)
Section 19A approval holder
Orspec Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
Pfizer (Australia) GENTAMICIN 80mg/2mL (as sulfate) injection BP ampoule - ARTG 11376
Indication(s)

For the treatment of infections due to one or more susceptible strains of bacteria, including Pseudomonas aeruginosa, Proteus species (indole positive and indole negative), Escherichia coli, Klebsiella, Enterobacter and Serratia species and Staphylococcus (including strains resistant to other antibiotics).

Gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. Aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics.

In suspected or documented Gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. Therapy may be instituted before obtaining results of susceptibility tests. The decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk of toxicity. If anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Images
Picture of gentamicin 40mg/mL solution for injection ampoules - carton

Help us improve the Therapeutic Goods Administration site